LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Akcijų sąrašas・MannKind Corp

MannKind Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

3.61 1.4

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.48

Max

3.73

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-671K -17M
Pardavimai	-22M 90M
P/E Sektoriaus vid.	140.5 49.888
Pelnas, tenkantis vienai akcijai	-0.02
Pelno marža	-18.431
Darbuotojai	591
EBITDA	5.9M 3.4M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+128.29% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	180M 1B
Ankstesnė atidarymo kaina	2.21
Ankstesnė uždarymo kaina	3.61

Naujienos nuotaikos

By Acuity

67%

33%

289 / 344 reitingas Healthcare

MannKind Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-09 23:49; UTC

Rinkos pokalbiai

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

2026-06-09 23:45; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

2026-06-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

2026-06-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

2026-06-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

2026-06-09 23:35; UTC

Rinkos pokalbiai

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

2026-06-09 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Additional Investment Makes It Largest Shareholder in Element

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

2026-06-09 20:51; UTC

Uždarbis

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-09 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-09 20:09; UTC

Rinkos pokalbiai

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

2026-06-09 19:36; UTC

Rinkos pokalbiai

Cattle Climbs as Crude Oil Falls -- Market Talk

2026-06-09 19:32; UTC

Rinkos pokalbiai

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

2026-06-09 19:25; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

2026-06-09 19:00; UTC

Rinkos pokalbiai

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

2026-06-09 18:52; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

2026-06-09 18:47; UTC

Rinkos pokalbiai

No World Cup Inflation Seen So Far in Mexico -- Market Talk

2026-06-09 18:37; UTC

Rinkos pokalbiai

Canada's Cooling Trade With the U.S. -- Market Talk

2026-06-09 18:27; UTC

Rinkos pokalbiai

Precious Metals Lower as Trump Vows Military Response -- Market Talk

2026-06-09 17:35; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

2026-06-09 17:30; UTC

Rinkos pokalbiai

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

2026-06-09 16:34; UTC

Rinkos pokalbiai

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2026-06-09 15:28; UTC

Rinkos pokalbiai

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

2026-06-09 15:25; UTC

Rinkos pokalbiai

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Akcijų palyginimas

Kainos pokytis

MannKind Corp Prognozė

Kainos tikslas

By TipRanks

128.29% į viršų

12 mėnesių prognozė

Vidutinis 8.15 USD 128.29%

Aukščiausias 11 USD

Žemiausias 4.75 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MannKind Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių MannKind Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

289 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.